Keyphrases
Bevacizumab
100%
Metastatic Colorectal Cancer (mCRC)
100%
Salvage Treatment
100%
Chemorefractory
100%
Bevacizumab Plus Chemotherapy
100%
Chemotherapy
50%
5-fluorouracil (5-FU)
37%
Irinotecan
37%
Conventional Chemotherapy
25%
Leucovorin
25%
Advanced Lines
25%
Monoclonal Antibody
12%
Disease Control
12%
Belgium
12%
Vascular Endothelial Growth Factor
12%
Treatment Failure
12%
Patient Selection
12%
Little Data
12%
Single-center Study
12%
University Hospital
12%
Treatment Regimen
12%
Antibody Targeting
12%
Cetuximab
12%
Anti-EGFR
12%
Objective Response
12%
Median Overall Survival
12%
Median Progression-free Survival
12%
Disease Control Rate
12%
Third-line Treatment
12%
Oxaliplatin
12%
Leuven
12%
Fourth Line
12%
FOLFOX
12%
Oxaliplatin Chemotherapy
12%
Oxaliplatin-based Chemotherapy
12%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Bevacizumab
100%
Metastatic Colorectal Cancer
100%
Fluorouracil
30%
Irinotecan
30%
Oxaliplatin
30%
Folinic Acid
20%
Diseases
20%
Population Study
10%
Vasculotropin
10%
Monoclonal Antibody
10%
Growth Factor Receptor
10%
Progression Free Survival
10%
Overall Survival
10%
Cetuximab
10%